132 related articles for article (PubMed ID: 38270081)
1. Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.
Jaffe GJ; Khanani AM
Immunotherapy; 2024 Mar; 16(4):205-221. PubMed ID: 38270081
[TBL] [Abstract][Full Text] [Related]
2. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
Liao DS; Metlapally R; Joshi P
Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
[TBL] [Abstract][Full Text] [Related]
4. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
5. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ; Khanani AM; Kaiser PK; Chang MA; Kovach JL; Lally DR; Rachitskaya A; Sheth VS; Vajzovic L; Clark J; Tang J; Zhu L; Desai D; Chakravarthy U
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38719191
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM; Patel SS; Staurenghi G; Tadayoni R; Danzig CJ; Eichenbaum DA; Hsu J; Wykoff CC; Heier JS; Lally DR; Monés J; Nielsen JS; Sheth VS; Kaiser PK; Clark J; Zhu L; Patel H; Tang J; Desai D; Jaffe GJ;
Lancet; 2023 Oct; 402(10411):1449-1458. PubMed ID: 37696275
[TBL] [Abstract][Full Text] [Related]
7. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
[TBL] [Abstract][Full Text] [Related]
8. A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan.
Patel NA; Hoyek S; Al-Khersan H; Yannuzzi NA; Smiddy WE
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38777140
[TBL] [Abstract][Full Text] [Related]
9. Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.
Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ; Dinah C
BMC Res Notes; 2023 Sep; 16(1):244. PubMed ID: 37777762
[TBL] [Abstract][Full Text] [Related]
10. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
12. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
Vakharia P; Eichenbaum D
Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
[TBL] [Abstract][Full Text] [Related]
13. Avacincaptad Pegol: First Approval.
Kang C
Drugs; 2023 Oct; 83(15):1447-1453. PubMed ID: 37814173
[TBL] [Abstract][Full Text] [Related]
14. Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.
Med Lett Drugs Ther; 2024 Jan; 66(1694):15-16. PubMed ID: 38212259
[No Abstract] [Full Text] [Related]
15. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
16. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
[TBL] [Abstract][Full Text] [Related]
17. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576-586).
Pfau M
Ophthalmology; 2021 Dec; 128(12):e219. PubMed ID: 34600774
[No Abstract] [Full Text] [Related]
18. SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
Song D; Hua P; VanderBeek BL; Dunaief JL; Grunwald JE; Daniel E; Maguire MG; Martin DF; Ying GS;
Retina; 2021 Jul; 41(7):1455-1462. PubMed ID: 33332813
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
